Trevi Therapeutics Inc [TRVI] stock is trading at $4.22, up 7.11%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TRVI shares have gain 6.30% over the last week, with a monthly amount glided 2.43%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Trevi Therapeutics Inc [NASDAQ: TRVI] stock has seen the most recent analyst activity on December 12, 2024, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $7.50 from $6. On August 30, 2024, Raymond James initiated with a Outperform rating and assigned a price target of $9 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $6 on August 30, 2024. Rodman & Renshaw initiated its recommendation with a Buy and recommended $7 as its price target on June 13, 2024. B. Riley Securities started tracking with a Buy rating for this stock on April 12, 2023, and assigned it a price target of $6. In a note dated November 22, 2022, SVB Leerink initiated an Outperform rating and provided a target price of $6 on this stock.
Trevi Therapeutics Inc [TRVI] stock has fluctuated between $1.35 and $4.68 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Trevi Therapeutics Inc [NASDAQ: TRVI] shares were valued at $4.22 at the most recent close of the market. An investor can expect a potential return of 42.18% based on the average TRVI price forecast.
Analyzing the TRVI fundamentals
Gross Profit Margin for this corporation currently stands at 0.39% with Operating Profit Margin at -273.95%, Pretax Profit Margin comes in at -251.97%, and Net Profit Margin reading is -251.8%. To continue investigating profitability, this company’s Return on Assets is posted at -0.64, Equity is -0.63 and Total Capital is -0.81. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.96 points at the first support level, and at 3.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.39, and for the 2nd resistance point, it is at 4.55.
Ratios To Look Out For
For context, Trevi Therapeutics Inc’s Current Ratio is 7.38. In addition, the Quick Ratio stands at 7.38 and the Cash Ratio stands at 1.76.
Transactions by insiders
Recent insider trading involved GOOD JENNIFER L, President & CEO, that happened on Sep 06 ’24 when 4219.0 shares were sold. President & CEO, GOOD JENNIFER L completed a deal on Sep 09 ’24 to sell 1840.0 shares. Meanwhile, President & CEO GOOD JENNIFER L sold 40277.0 shares on Sep 05 ’24.
